Improved Cardiovascular Health for Patients With Inflammatory Joint Diseases

Rheumatoid Arthritis Clinical Trial

— ExeHeart  

Official title:

Improved Cardiovascular Health for Patients With Inflammatory Joint Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04922840
• Other study ID #: 2021/FO347439
• Status: Completed
• Phase: N/A
• Start date: August 9, 2021
• Est. completion date: March 1, 2023

Study information

• Verified date: March 2023
• Source: Diakonhjemmet Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Inflammatory joint diseases (IJD) are autoimmune diseases with common symptoms of joint inflammation, pain, stiffness and fatigue. Compared to the general population, this large patient-group has an increased risk of cardiovascular disease (CVD) and CVD-related mortality. Patients with IJD call for improved CVD screening and risk management as well as access to evidence-based non-pharmacological treatment alternatives. Evidence supports high intensity training (HIIT) in mitigating risk of CVD and inflammation, but the evidence of these cardioprotective benefits is unclear in patients with IJD and the feasibility of HIIT protocols in daily clinical care needs to be addressed. Cardiorespiratory fitness (CRF) is an important physiological marker and highly correlated to risk of CVD. Despite strong recommendations, routine assessment of CRF is seldom performed in clinical care.

The ExeHeart study will assess the potential cardioprotective and disease-modifying effect of HIIT in IJD in a randomized controlled trial. Furthermore, the ExeHeart-study will report on the validity of non-exercise measures of cardiorespiratory fitness (eCRF) measures for use in daily clinical care. Additionally, we will explore the feasibility of HIIT by addressing adherence and fidelity to the HIIT treatment protocol in a primary care setting

Description:

The study is a two-armed randomized controlled trial (RCT). Patients aged 18-70 years presenting with inflammatory joint disease at the Preventive Cardio-Rheuma clinic at Diakonhjemmet hospital (Oslo) will be included if eligible for the study. Succeeding baseline testing, participants are randomized to either experimental group (high-intensity exercise-HIIT) or control group (usual care).

The research questions are:

1. Is a 12-week HIIT program effective on VO2peak, inflammatory markers and risk of cardiovascular disease in patients with inflammatory joint disease and what is the association between VO2peak and disease-specific and cardiovascular disease-related variables?

2. Is a non-exercise cardio-respiratory fitness algorithm (eCRF) valid in determining longitudinal change in VO2peak in patients with inflammatory joint disease?

3. How feasible is a HIIT intervention in primary care in patients with inflammatory joint disease in terms of adherence and fidelity to the exercise program?

The primary analysis will be a between group comparison of VO2peak levels. This will be carried out according to the intention-to-treat principle, and done by the analysis of covariance (ANCOVA), adjusting for VO2peak values at baseline along with stratification factors used in the randomization. Secondary analyses will include between group comparisons on secondary endpoints, as well as comparisons in the per protocol population. No adjustment for multiple testing will be done.

The association between VO2peak and changes in inflammatory markers, disease activity and CVD risk will be assessed using multiple regression.

The validity of eCRF models to accurately detect longitudinal change in VO2peak from baseline to 3-month and 6-month follow-up will be assessed with Pearson or Spearman correlation by comparing VO2peak derived from a cardiopulmonary exercise test to eCRF.

The feasibility of a HIIT program and adherence will be examined with descriptive statistics. Adherence to the prescribed HIIT intervention will be recorded by attendance to exercise sessions. Quality of treatment delivery will be quantified as the number of exercise sessions complying with the planned exercise intensity and number of exercise sessions requiring dose modifications such as lower exercise intensity or early session termination. At the 3-month timepoint, an electronic questionnaire will be distributed to patients in the HIIT group. Questions regarding feasibility and implementation fidelity will address patients' acceptability and satisfaction with the HIIT program. The ExeHeart study will also include semi-structured interviews, targeting physiotherapists in charge of supervising the exercise sessions and 5-7 patients in the intervention group. The interviews will explore barriers and facilitators in exercise adherence, experience with the protocol and perceived effects of exercise.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 1, 2023
• Est. primary completion date: December 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age: 18-70

• BMI: 18.5-40

• Inflammatory joint disease verified by physician

• Able to walk unaided and continuously for = 15 min.

• Norwegian or English speaking

Exclusion Criteria:

• Sustained lower extremity injury =12 months, including surgery

• Neurological disease

• Absolute contraindication to maximal exercise test

• Cognitive impairment

• Participation in structured high-intensity exercise = 1/week in the last 3 months

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Joint Diseases
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylarthritis
• Spondylitis
• Spondyloarthritis

Intervention

Behavioral:
• High-intensity exercise (HIIT)
12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.

Locations

Country	Name	City	State
Norway	Diakonhjemmet Hospital	Oslo

Sponsors (4)

Lead Sponsor	Collaborator
Diakonhjemmet Hospital	Norwegian Health Association, The Dam Foundation, The Norwegian Rheumatism Association

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak oxygen uptake - VO2peak ml/kg/min	VO2peak, expressed in milliliters of oxygen per kilogram of body weight per minute (ml/kg/min). VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion	3 months post baseline
Secondary	Peak oxygen uptake - VO2peak L/min	VO2peak, expressed in liters per minute. VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion	3 months post baseline
Secondary	Peak oxygen uptake - VO2peak ml/kg/min	VO2peak, expressed in milliliters of oxygen per kilogram of body weight per minute (ml/kg/min). VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion (RPE 0-10)	Baseline
Secondary	Peak oxygen uptake - VO2peak ml/kg/min	VO2peak, expressed in milliliters of oxygen per kilogram of body weight per minute (ml/kg/min). VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion (RPE 0-10)	6 months post baseline
Secondary	Peak oxygen uptake - VO2peak L/min	VO2peak, expressed in liters per minute. VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion (RPE 0-10)	Baseline
Secondary	Peak oxygen uptake - VO2peak L/min	VO2peak, expressed in liters per minute. VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion (RPE 0-10)	6 months post baseline
Secondary	Change in VO2peak (ml/kg/min) from baseline to 3 months past baseline	Change in VO2peak, expressed in milliliters of oxygen per kilogram of body weight per minute from baseline to 6 months (3 months post intervention) . VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion	3 months post baseline
Secondary	Change in VO2peak (ml/kg/min) from baseline to 6 months post baseline	Change in VO2peak, expressed in milliliters of oxygen per kilogram of body weight per minute from baseline to 6 months (3 months post intervention) . VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion	6 months
Secondary	Change in VO2peak L/min from baseline to 3 months post baseline	VO2peak, expressed in liters per minute(L/min). VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion	3 months post baseline
Secondary	Change in VO2peak L/min from baseline to 6 months post baseline	VO2peak, expressed in liters per minute(L/min). VO2peak will be measured by a Cardiopulmonary Exercise test (CPET) on a treadmill, using electrocardiogram (ECG), breath-by-breath gas analyzing system, blood pressure (BP) monitor, pulse oximetry, and Borg rating of perceived exertion	6 months post baseline
Secondary	Body composition	Body scan to estimate total and regional distribution of lean body mass and fat mass	Baseline
Secondary	Body composition	Body scan to estimate total and regional distribution of lean body mass and fat mass	3 months post baseline
Secondary	Body composition	Body scan to estimate total and regional distribution of lean body mass and fat mass	6 months post baseline
Secondary	Ventilatory threshold 1	Point during at which ventilation starts to increase at a faster rate than VO2 - derived from CPET	Baseline
Secondary	Ventilatory threshold 1	Point during exercise at which ventilation starts to increase at a faster rate than VO2 - derived from CPET	3 months post baseline
Secondary	Ventilatory threshold 1	Point during exercise at which ventilation starts to increase at a faster rate than volume of oxygen (VO2) - derived from CPET	6 months post baseline
Secondary	Ventilatory threshold 2	The point at which the oxygen demand of the muscles exceeds the ability of the cardiopulmonary system to supply oxygen- derived from CPET	Baseline
Secondary	Ventilatory threshold 2	The point at which the oxygen demand of the muscles exceeds the ability of the cardiopulmonary system to supply oxygen- derived from CPET	3 months post baseline
Secondary	Ventilatory threshold 2	The point at which the oxygen demand of the muscles exceeds the ability of the cardiopulmonary system to supply oxygen- derived from CPET	6 months post baseline
Secondary	Breathing reserve	Difference between the maximal voluntary ventilation (MVV) and the maximum ventilation measured during CPET	Baseline
Secondary	Breathing reserve	Difference between the maximal voluntary ventilation (MVV) and the maximum ventilation measured during CPET	3 months post baseline
Secondary	Breathing reserve	Difference between the maximal voluntary ventilation (MVV) and the maximum ventilation measured during CPET	6 months post baseline
Secondary	Oxygen pulse	The oxygen pulse is the oxygen (O2) divided by heart rate, and represents the product of the stroke volume and the arterial-venous oxygen difference. Derived from CPET.	Baseline
Secondary	Oxygen pulse	The oxygen pulse is the oxygen (O2) divided by heart rate, and represents the product of the stroke volume and the arterial-venous oxygen difference. Derived from CPET.	3 months post baseline
Secondary	Oxygen pulse	The oxygen pulse is the oxygen (O2) divided by heart rate, and represents the product of the stroke volume and the arterial-venous oxygen difference. Derived from CPET.	6 months post baseline
Secondary	Ventilatory equivalents for oxygen (VE/VO2)	Ratio of the volume of gas expired per minute to the volume of oxygen consumed per minute- derived from CPET	Baseline
Secondary	Ventilatory equivalents for oxygen (VE/VO2)	Ratio of the volume of gas expired per minute to the volume of oxygen consumed per minute- derived from CPET	3 months post baseline
Secondary	Ventilatory equivalents for oxygen (VE/VO2)	Ratio of the volume of gas expired per minute to the volume of oxygen consumed per minute- derived from CPET	6 months post baseline
Secondary	Ventilatory equivalents for carbon dioxide(VE/VCO2)	Ratio of the volume of gas expired per minute to the volume of carbon dioxide produced per minute- derived from CPET	Baseline
Secondary	Ventilatory equivalents for carbon dioxide(VE/VCO2)	Ratio of the volume of gas expired per minute to the volume of carbon dioxide produced per minute- derived from CPET	3 months post baseline
Secondary	Ventilatory equivalents for carbon dioxide (VE/VCO2)	Ratio of the volume of gas expired per minute to the volume of carbon dioxide produced per minute- derived from CPET	6 months post baseline
Secondary	Respiratory Exchange Ratio (RER)	Ratio of carbon dioxide output/oxygen uptake (VCO2/VO2) at peak exercise intensity - derived from CPET	Baseline
Secondary	Respiratory Exchange Ratio (RER)	Ratio of carbon dioxide output/oxygen uptake (VCO2/VO2) at peak exercise intensity - derived from CPET	3 months post baseline
Secondary	Respiratory Exchange Ratio (RER)	Ratio of carbon dioxide output/oxygen uptake (VCO2/VO2) at peak exercise intensity - derived from CPET	6 months post baseline
Secondary	Blood lactate concentration	Sampled from fingertip within 60 sec of CPET completion to assess level of anaerobic processes	Baseline
Secondary	Blood lactate concentration	Sampled from fingertip within 60 sec of CPET completion to assess level of anaerobic processes	3 months post baseline
Secondary	Blood lactate concentration	Sampled from fingertip within 60 sec of CPET completion to assess level of anaerobic processes	6 months post baseline
Secondary	C-Reactive protein	Non-fasting blood samples are measured at the hospital laboratory and analysed for C-Reactive protein	Baseline
Secondary	C-Reactive protein	Non-fasting blood samples are measured at the hospital laboratory and analysed for C-Reactive protein	3 months post baseline
Secondary	C-Reactive protein	Non-fasting blood samples are measured at the hospital laboratory and analysed for C-Reactive protein	6 months post baseline
Secondary	Erythrocyte Sedimentation Rate	Non-fasting blood samples are measured at the hospital laboratory and analysed for Erythrocyte Sedimentation Rate	Baseline
Secondary	Erythrocyte Sedimentation Rate	Non-fasting blood samples are measured at the hospital laboratory and analysed for Erythrocyte Sedimentation Rate	3 months post baseline
Secondary	Erythrocyte Sedimentation Rate	Non-fasting blood samples are measured at the hospital laboratory and analysed for Erythrocyte Sedimentation Rate	6 months post baseline
Secondary	Total cholesterol	Non-fasting blood samples are measured at the hospital laboratory and analysed for total cholesterol	Baseline
Secondary	Total cholesterol	Non-fasting blood samples are measured at the hospital laboratory and analysed for total cholesterol	3 months post baseline
Secondary	Total cholesterol	Non-fasting blood samples are measured at the hospital laboratory and analysed for total cholesterol	6 months post baseline
Secondary	High-density lipoproteins	Non-fasting blood samples are measured at the hospital laboratory and analysed for high-density lipoproteins	Baseline
Secondary	High-density lipoproteins	Non-fasting blood samples are measured at the hospital laboratory and analysed for high-density lipoproteins	3 months post baseline
Secondary	High-density lipoproteins	Non-fasting blood samples are measured at the hospital laboratory and analysed for high-density lipoproteins	6 months post baseline
Secondary	Low-density lipoproteins	Non-fasting blood samples are measured at the hospital laboratory and analysed for low-density lipoproteins	Baseline
Secondary	Low-density lipoproteins	Non-fasting blood samples are measured at the hospital laboratory and analysed for low-density lipoproteins	3 months post baseline
Secondary	Low-density lipoproteins	Non-fasting blood samples are measured at the hospital laboratory and analysed for low-density lipoproteins	6 months post baseline
Secondary	Triglycerides	Non-fasting blood samples are measured at the hospital laboratory and analysed for triglycerides	Baseline
Secondary	Triglycerides	Non-fasting blood samples are measured at the hospital laboratory and analysed for triglycerides	3 months post baseline
Secondary	Triglycerides	Non-fasting blood samples are measured at the hospital laboratory and analysed for triglycerides	6 months post baseline
Secondary	Blood pressure	Supine systolic and diastolic blood pressure	Baseline
Secondary	Blood pressure	Supine systolic and diastolic blood pressure	3 months post baseline
Secondary	Blood pressure	Supine systolic and diastolic blood pressure	6 months post baseline
Secondary	Body Mass Index	Weight in kilograms divided by the square of height in meters	Baseline
Secondary	Body Mass Index	Weight in kilograms divided by the square of height in meters	3 months post baseline
Secondary	Body Mass Index	Weight in kilograms divided by the square of height in meters	6 months post baseline
Secondary	Waist circumference	Waist girth in centimeters. Measured in a standing position after a full exhale.	Baseline
Secondary	Waist circumference	Waist girth in centimeters. Measured in a standing position after a full exhale.	3 months post baseline
Secondary	Waist circumference	Waist girth in centimeters. Measured in a standing position after a full exhale.	6 months post baseline
Secondary	Resting heart rate	Recorded in conjunction with blood pressure measurement at rest- resting supine on a bench	Baseline
Secondary	Resting heart rate	Recorded in conjunction with blood pressure measurement at rest- resting supine on a bench	3 months post baseline
Secondary	Resting heart rate	Recorded in conjunction with blood pressure measurement at rest- resting supine on a bench	6 months post baseline
Secondary	Health-related quality of life, EuroQoL (EQ5D-5L)	Health-related quality of life is measured by the EQ5D-5L questionnaire. Patients are asked to answer their ability to perform walking, personal care and activities of daily life on a 5 point Likert scale from no difficulties to not able to. Pain and anxiety/depression is measured on a 5 point Likert scale from no pain to very strong pain, and no anxiety/depression to extremely anxious/depressed. General experience of health is measured from 0 (worst health) to 100 (best health) on a numeric rating scale.	Baseline
Secondary	Health-related quality of life, EuroQoL (EQ5D-5L)	Health-related quality of life is measured by the EQ5D-5L questionnaire. Patients are asked to answer their ability to perform walking, personal care and activities of daily life on a 5 point Likert scale from no difficulties to not able to. Pain and anxiety/depression is measured on a 5 point Likert scale from no pain to very strong pain, and no anxiety/depression to extremely anxious/depressed. General experience of health is measured from 0 (worst health) to 100 (best health) on a numeric rating scale.	3 months post baseline
Secondary	Health-related quality of life, EuroQoL (EQ5D-5L)	Health-related quality of life is measured by the EQ5D-5L questionnaire. Patients are asked to answer their ability to perform walking, personal care and activities of daily life on a 5 point Likert scale from no difficulties to not able to. Pain and anxiety/depression is measured on a 5 point Likert scale from no pain to very strong pain, and no anxiety/depression to extremely anxious/depressed. General experience of health is measured from 0 (worst health) to 100 (best health) on a numeric rating scale.	6 months post baseline
Secondary	Frequency of medication	Usage of medications last three months. Measured in frequency.	Baseline
Secondary	Dosage of medication	Usage of medications last three months. Measured in dosage.	Baseline
Secondary	Dosage of medication	Usage of medications last three months. Measured in dosage	3 months post baseline
Secondary	Frequency of medication	Usage of medications last three months. Measured in frequency	3 months post baseline
Secondary	Dosage of medication	Usage of medications last three months. Measured in dosage.	6 months post baseline
Secondary	Frequency of medication	Usage of medications last three months. Measured in frequency.	6 months post baseline
Secondary	Self-reported fatigue	Last week's experience of fatigue is measured on a Numeric rating scale from 0 (No fatigue) to 10 (Worst imaginable fatigue).	Baseline
Secondary	Self-reported fatigue	Last week's experience of fatigue is measured on a Numeric rating scale from 0 (No fatigue) to 10 (Worst imaginable fatigue).	3 months post baseline
Secondary	Self-reported fatigue	Last week's experience of fatigue is measured on a Numeric rating scale from 0 (No fatigue) to 10 (Worst imaginable fatigue).	6 months post baseline
Secondary	Self-reported pain	Last week's experience of pain measured by numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain).	Baseline
Secondary	Self-reported pain	Last week's experience of pain measured by numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain).	3 months post baseline
Secondary	Self-reported pain	Last week's experience of pain measured by numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain).	6 months post baseline
Secondary	Self-reported physical activity (HUNT)	Measured by questions from the Nord-Trøndelag Health study (HUNT): average frequency (never/<1 per week/1 per week/2-3 per week/almost every day), intensity (easy without losing my breath or breaking into a sweat/so hard that I lose my breath and break into a sweat/I push myself to near-exhaustion) and duration (less than 15 minutes/15-29 minutes/30 minutes to 1 hour/more than 1 hour) of physical activity.	Baseline
Secondary	Self-reported physical activity (HUNT)	Measured by questions from the Nord-Trøndelag Health study (HUNT): average frequency (never/<1 per week/1 per week/2-3 per week/almost every day), intensity (easy without losing my breath or breaking into a sweat/so hard that I lose my breath and break into a sweat/I push myself to near-exhaustion) and duration (less than 15 minutes/15-29 minutes/30 minutes to 1 hour/more than 1 hour) of physical activity.	3 months post baseline
Secondary	Self-reported physical activity (HUNT)	Measured by questions from the Nord-Trøndelag Health study (HUNT): average frequency (never/<1 per week/1 per week/2-3 per week/almost every day), intensity (easy without losing my breath or breaking into a sweat/so hard that I lose my breath and break into a sweat/I push myself to near-exhaustion) and duration (less than 15 minutes/15-29 minutes/30 minutes to 1 hour/more than 1 hour) of physical activity.	6 months post baseline
Secondary	SCORE2	Systemic Coronary Risk Estimation 2 Evaluation: Age, sex, smoking status, non-HDL blood cholesterol and systolic blood pressure is used to estimate 10-year risk of fatal and non-fatal cardiovascular disease.	Baseline
Secondary	SCORE2	Systemic Coronary Risk Estimation 2 Evaluation: Age, sex, smoking status, non-HDL blood cholesterol and systolic blood pressure is used to estimate 10-year risk of fatal and non-fatal cardiovascular disease.	3 months post baseline
Secondary	SCORE2	Systemic Coronary Risk Estimation 2 Evaluation: Age, sex, smoking status, non-HDL blood cholesterol and systolic blood pressure is used to estimate 10-year risk of fatal and non-fatal cardiovascular disease.	6 months post baseline
Secondary	Forced vital capacity	Volume of air that can be forcefully exhaled after a full inspiration, measured in liters. Obtained from spirometry	Baseline
Secondary	Forced vital capacity	Volume of air that can be forcefully exhaled after a full inspiration, measured in liters- obtained from spirometry	3 months post baseline
Secondary	Forced vital capacity	Volume of air that can be forcefully exhaled after a full inspiration, measured in liters- obtained from spirometry	6 months post baseline
Secondary	Forced expiratory volume in 1 second (FEV1)	Volume of air that can be forcefully exhaled in the first second after a full inspiration, measured in liters- obtained by spirometry	Baseline
Secondary	Forced expiratory volume in 1 second (FEV1)	Volume of air that can be forcefully exhaled in the first second after a full inspiration, measured in liters- obtained by spirometry	3 months post baseline
Secondary	Forced expiratory volume in 1 second (FEV1)	Volume of air that can be forcefully exhaled in the first second after a full inspiration, measured in liters- obtained by spirometry	6 months post baseline
Secondary	FEV1/FVC ratio	Ratio (%) of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC)	Baseline
Secondary	FEV1/FVC ratio	Ratio (%) of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC)	3 months post baseline
Secondary	FEV1/FVC ratio	Ratio (%) of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC)	6 months post baseline
Secondary	Forced expiratory flow	Speed of air during the middle part of a forced expiration, intervals at 25%, 50% and 75% of exhaled FVC, measured in liter per second (L/s) - obtained by spirometry	Baseline
Secondary	Forced expiratory flow	Speed of air during the middle part of a forced expiration, intervals at 25%, 50% and 75% of exhaled FVC, measured in liter per second (L/s) - obtained by spirometry	3 months post baseline
Secondary	Forced expiratory flow	Speed of air during the middle part of a forced expiration, intervals at 25%, 50% and 75% of exhaled FVC, measured in liter per second (L/s) - obtained by spirometry	6 months post baseline
Secondary	Peak expiratory flow (PEF)	Maximum speed of expiration, expressed in liters per minute (L/min)- obtained from spirometry	Baseline
Secondary	Peak expiratory flow (PEF)	Maximum speed of expiration, expressed in liters per minute (L/min)- obtained from spirometry	3 months post baseline
Secondary	Peak expiratory flow (PEF)	Maximum speed of expiration, expressed in liters per minute (L/min)- obtained from spirometry	6 months post baseline
Secondary	Maximum voluntary ventilation (MVV)	Measure of the maximum amount of air that can be inhaled and exhaled in one minute. Measured over a 6- or 12-second time period, extrapolated to a value for one minute, expressed in liters/minute (L/min)- obtained from spirometry	Baseline
Secondary	Maximum voluntary ventilation (MVV)	Measure of the maximum amount of air that can be inhaled and exhaled in one minute. Measured over a 6- or 12-second time period, extrapolated to a value for one minute, expressed in liters/minute (L/min)- obtained from spirometry	3 months post baseline
Secondary	Maximum voluntary ventilation (MVV)	Measure of the maximum amount of air that can be inhaled and exhaled in one minute. Measured over a 6- or 12-second time period, extrapolated to a value for one minute, expressed in liters/minute (L/min)- obtained from spirometry	6 months post baseline
Secondary	Psoriatic Arthritis Impact of Disease (PsAID)	Patient-reported outcome measure for assessing psoriatic arthritis. Calculated based on 9 Numerical rating scales (NRS) questions regarding pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping and anxiety. Each NRS is assessed as a number between 0 and 10. Range of final PsAID value is 0-10 where higher figures indicate worse status. Relevant for study participants with psoriatic arthritis.	Baseline
Secondary	Psoriatic Arthritis Impact of Disease (PsAID)	Patient-reported outcome measure for assessing psoriatic arthritis. Calculated based on 9 Numerical rating scales (NRS) questions regarding pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping and anxiety. Each NRS is assessed as a number between 0 and 10. Range of final PsAID value is 0-10 where higher figures indicate worse status. Relevant for study participants psoriatic arthritis.	3 months post baseline
Secondary	Psoriatic Arthritis Impact of Disease (PsAID)	Patient-reported outcome measure for assessing psoriatic arthritis. Calculated based on 9 Numerical rating scales (NRS) questions regarding pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping and anxiety. Each NRS is assessed as a number between 0 and 10. Range of final PsAID value is 0-10 where higher figures indicate worse status. Relevant for study participants with psoriatic arthritis.	6 months post baseline
Secondary	Rheumatoid arthritis impact of disease (RAID)	Patient-reported outcome measure for assessing rheumatoid arthritis. Calculated based on 7 Numerical rating scales (NRS) questions regarding pain, functional capacity, fatigue, physical wellbeing, emotional wellbeing, quality of sleep and coping. Each NRS is assessed as a number between 0 and 10. Range of final RAID value is 0-10 where higher figures indicate worse status. Relevant for study participants with rheumatoid arthritis.	Baseline
Secondary	Rheumatoid arthritis impact of disease (RAID)	Patient-reported outcome measure for assessing rheumatoid arthritis. Calculated based on 7 Numerical rating scales (NRS) questions regarding pain, functional capacity, fatigue, physical wellbeing, emotional wellbeing, quality of sleep and coping. Each NRS is assessed as a number between 0 and 10. Range of final RAID value is 0-10 where higher figures indicate worse status. Relevant for study participants with rheumatoid arthritis.	3 months post baseline
Secondary	Rheumatoid arthritis impact of disease (RAID)	Patient-reported outcome measure for assessing rheumatoid arthritis. Calculated based on 7 Numerical rating scales (NRS) questions regarding pain, functional capacity, fatigue, physical wellbeing, emotional wellbeing, quality of sleep and coping. Each NRS is assessed as a number between 0 and 10. Range of final RAID value is 0-10 where higher figures indicate worse status. Relevant for study participants with rheumatoid arthritis.	6 months post baseline
Secondary	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)	Patient-reported outcome measure for assessing ankylosing spondylitis. Calculated based on 6 Numerical rating scales (NRS) questions regarding fatigue, pain, spinal pain, joint pain, pain on palpation of areas with localized tenderness, morning stiffness severity and morning stiffness duration. Each NRS is assessed as a number between 0 and 10. Range of final BASDAI value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	Baseline
Secondary	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)	Patient-reported outcome measure for assessing ankylosing spondylitis. Calculated based on 6 Numerical rating scales (NRS) questions regarding fatigue, pain, spinal pain, joint pain, pain on palpation of areas with localized tenderness, morning stiffness severity and morning stiffness duration. Each NRS is assessed as a number between 0 and 10. Range of final BASDAI value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	3 months post baseline
Secondary	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)	Patient-reported outcome measure for assessing ankylosing spondylitis. Calculated based on 6 Numerical rating scales (NRS) questions regarding fatigue, pain, spinal pain, joint pain, pain on palpation of areas with localized tenderness, morning stiffness severity and morning stiffness duration. Each NRS is assessed as a number between 0 and 10. Range of final BASDAI value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	6 months post baseline
Secondary	Bath Ankylosing Spondylitis Functional Index (BASFI)	Patient-reported outcome measure for assessing functional limitation in patients with ankylosing spondylitis. Calculated based on 10 Numerical rating scales (NRS) questions, 8 questions regarding functional limitations and 2 questions regarding the ability to cope with everyday life. Each NRS is assessed as a number between 0 and 10. Range of final BASFI value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	Baseline
Secondary	Bath Ankylosing Spondylitis Functional Index (BASFI)	Patient-reported outcome measure for assessing functional limitation in patients with ankylosing spondylitis. Calculated based on 10 Numerical rating scales (NRS) questions, 8 questions regarding functional limitations and 2 questions regarding the ability to cope with everyday life. Each NRS is assessed as a number between 0 and 10. Range of final BASFI value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	3 months post baseline
Secondary	Bath Ankylosing Spondylitis Functional Index (BASFI)	Patient-reported outcome measure for assessing functional limitation in patients with ankylosing spondylitis. Calculated based on 10 Numerical rating scales (NRS) questions, 8 questions regarding functional limitations and 2 questions regarding the ability to cope with everyday life. Each NRS is assessed as a number between 0 and 10. Range of final BASFI value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	6 months post baseline
Secondary	Bath Ankylosing Spondylitis Global Score (BAS-G)	Patient-reported outcome measure for assessing ankylosing spondylitis. Calculated based on 2 Numerical rating scales (NRS) questions regarding patients's well-being the previous week and previous six months. Range of final BAS-G value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	Baseline
Secondary	Bath Ankylosing Spondylitis Global Score (BAS-G)	Patient-reported outcome measure for assessing ankylosing spondylitis. Calculated based on 2 Numerical rating scales (NRS) questions regarding patients's well-being the previous week and previous six months. Range of final BAS-G value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	3 months post baseline
Secondary	Bath Ankylosing Spondylitis Global Score (BAS-G)	Patient-reported outcome measure for assessing ankylosing spondylitis. Calculated based on 2 Numerical rating scales (NRS) questions regarding patients's well-being the previous week and previous six months. Range of final BAS-G value is 0-10 where higher figures indicate worse status. Relevant for study participants with spondyloarthritis.	6 months post baseline
Secondary	Ankylosing Spondylitis Disease Activity Score (ASDAS)	Composite score to assess disease activity in ankylosing spondylitis. Calculated based on three questions from BASDAI, patient global assessment on 0-10 scale and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with spondyloarthritis.	3 months post baseline
Secondary	Ankylosing Spondylitis Disease Activity Score (ASDAS)	Composite score to assess disease activity in ankylosing spondylitis. Calculated based on three questions from BASDAI, patient global assessment on 0-10 scale and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with spondyloarthritis.	6 months post baseline
Secondary	Ankylosing Spondylitis Disease Activity Score (ASDAS)	Composite score to assess disease activity in ankylosing spondylitis. Calculated based on three questions from BASDAI, patient global assessment on 0-10 scale and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with spondyloarthritis.	Baseline
Secondary	Disease Activity Score Calculator for Rheumatoid Arthritis (DAS28)	Composite score to assess disease activity in rheumatoid arthritis. Calculated based on number of swollen (0-28) and tender joints (0-28), patient global assessment of health and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with rheumatoid arthritis.	Baseline
Secondary	Disease Activity Score Calculator for Rheumatoid Arthritis (DAS28)	Composite score to assess disease activity in rheumatoid arthritis. Calculated based on number of swollen (0-28) and tender joints (0-28), patient global assessment of health and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with rheumatoid arthritis.	3 months post baseline
Secondary	Disease Activity Score Calculator for Rheumatoid Arthritis (DAS28)	Composite score to assess disease activity in rheumatoid arthritis. Calculated based on number of swollen (0-28) and tender joints (0-28), patient global assessment of health and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with rheumatoid arthritis.	6 months post baseline
Secondary	Disease Activity in PSoriatic Arthritis (DAPSA)	Composite score to assess disease activity in psoriatic arthritis. Calculated based on number of swollen (0-66) and tender joints (0-68), patient global assessment of health and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with psoriatic arthritis	Baseline
Secondary	Disease Activity in PSoriatic Arthritis (DAPSA)	Composite score to assess disease activity in psoriatic arthritis. Calculated based on number of swollen (0-66) and tender joints (0-68), patient global assessment of health and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with psoriatic arthritis	3 months post baseline
Secondary	Disease Activity in PSoriatic Arthritis (DAPSA)	Composite score to assess disease activity in psoriatic arthritis. Calculated based on number of swollen (0-66) and tender joints (0-68), patient global assessment of health and C-Reactive Protein or Erythrocyte Sedimentation Rate from blood samples. Relevant for study participants with psoriatic arthritis	6 months post baseline
Secondary	Post-exercise questionnaire	Electronic questionnaire distributed to patients in the experimental group upon completion of HIT intervention. 14 statements related to participation in the HIT exercise intervention and perceived intensity, duration and frequency of the exercise intervention. Scored on a 5 point Likert scale ranging from strongly disagree to strongly agree.	3 months post baseline
Secondary	Use of healthcare services	Use of health care services is measured by number of consultations to general practitioner, medical specialist, physiotherapist, occupational therapist, Healthy Life Centres, psychologist in the last three months.	Baseline
Secondary	Use of healthcare services	Use of health care services is measured by number of consultations to general practitioner, medical specialist, physiotherapist, occupational therapist, Healthy Life Centres, psychologist in the last three months.	3 months post baseline
Secondary	Use of healthcare services	Use of health care services is measured by number of consultations to general practitioner, medical specialist, physiotherapist, occupational therapist, Healthy Life Centres, psychologist in the last three months.	6 months post baseline
Secondary	Smoking status	Registered by self-report; I smoke daily, I am a former smoker , I have never smoked	Baseline
Secondary	Smoking status	Registered by self-report; I smoke daily, I am a former smoker , I have never smoked	3 months post baseline
Secondary	Smoking status	Registered by self-report; I smoke daily, I am a former smoker , I have never smoked	6 months post baseline
Secondary	Snuff status	Registered by self-report; I use snuff daily, I have previously used snuff, I have never used snuff	Baseline
Secondary	Snuff status	Registered by self-report; I use snuff daily, I have previously used snuff, I have never used snuff	3 months post baseline
Secondary	Snuff status	Registered by self-report; I use snuff daily, I have previously used snuff, I have never used snuff	6 months post baseline
Secondary	Peak heart rate	Peak heart rate observed during CPET	Baseline
Secondary	Peak heart rate	Peak heart rate observed during CPET	3 months post baseline
Secondary	Peak heart rate	Peak heart rate observed during CPET	6 months post baseline
Secondary	Augmentation index	Indicator of arterial stiffness, measured by mobil-o-graph at the same time as measure of blood pressure	Baseline
Secondary	Augmentation index	Indicator of arterial stiffness, measured by mobil-o-graph at the same time as measure of blood pressure	3 months post baseline
Secondary	Augmentation index	Indicator of arterial stiffness, measured by mobil-o-graph at the same time as measure of blood pressure	6 months post baseline
Secondary	Pulse Wave Velocity	Measure of arterial stiffness- rate at which blood propagates through the vessels. Measured by moil-o-graph at the same time as measure of blood pressure	Baseline
Secondary	Pulse Wave Velocity	Measure of arterial stiffness- rate at which blood propagates through the vessels. Measured by moil-o-graph at the same time as measure of blood pressure	3 months post baseline
Secondary	Pulse Wave Velocity	Measure of arterial stiffness- rate at which blood propagates through the vessels. Measured by moil-o-graph at the same time as measure of blood pressure	6 months post baseline
Secondary	Exercise self-efficacy	Measured by Exercise Beliefs and Exercise Habits questionnaire: comprises 20 items addressing exercise self-efficacy (4 items), barriers to exercise (3 items), benefits of exercise (5 items), and impact of exercise on arthritis (8 items), scored on a 5-point Likert scale ranging from strongly disagree to strongly agree. The scores on each subscale is summed up where higher scores indicate better self-efficacy.	Baseline
Secondary	Exercise self-efficacy	Measured by Exercise Beliefs and Exercise Habits questionnaire: comprises 20 items addressing exercise self-efficacy (4 items), barriers to exercise (3 items), benefits of exercise (5 items), and impact of exercise on arthritis (8 items), scored on a 5-point Likert scale ranging from strongly disagree to strongly agree. The scores on each subscale is summed up where higher scores indicate better self-efficacy.	3 months post baseline
Secondary	Exercise self-efficacy	Measured by Exercise Beliefs and Exercise Habits questionnaire: comprises 20 items addressing exercise self-efficacy (4 items), barriers to exercise (3 items), benefits of exercise (5 items), and impact of exercise on arthritis (8 items), scored on a 5-point Likert scale ranging from strongly disagree to strongly agree. The scores on each subscale is summed up where higher scores indicate better self-efficacy.	6 months post baseline
Secondary	Exercise frequency	Participants in the experimental group are asked to record individual exercise session in a training diary. Exercise frequency is recorded.	3 months post baseline
Secondary	Exercise intensity	Participants in the experimental group are asked to record individual exercise session in a training diary. Exercise intensity is recorded by use of a herat rate monitor.	3 months post baseline
Secondary	Exercise duration	Participants in the experimental group are asked to record individual exercise session in a training diary. Exercise duration is recorded.	3 months post baseline
Secondary	Early session termination	Participants in the experimental group are asked to record individual exercise session in a training diary. Early session termination is recorded.	3 months post baseline
Secondary	Exercise-related adverse events	Participants in the experimental group are asked to record individual exercise session in a training diary. Exercise-related adverse events are recorded.	3 months post baseline
Secondary	Self-reported cardiovascular health and symptoms	13 yes/no questions regarding self-report of cardiovascular disease, symptoms and cardiac surgery. If the participant answers yes to preliminary question regarding angina, 5 ancillary questions pertaining to angina symptomatology are provided	Baseline
Secondary	Self-reported cardiovascular health and symptoms	13 yes/no questions regarding self-report of cardiovascular disease, symptoms and cardiac surgery. If the participant answers yes to preliminary question regarding angina, 5 ancillary questions pertaining to angina symptomatology are provided	3 months post baseline
Secondary	Self-reported cardiovascular health and symptoms	13 yes/no questions regarding self-report of cardiovascular disease, symptoms and cardiac surgery. If the participant answers yes to preliminary question regarding angina, 5 ancillary questions pertaining to angina symptomatology are provided	6 months post baseline
Secondary	Self-report change in physical fitness	Patient global change in self-perceived physical fitness measured on a 5-point Likert scale ranging from much better to much worse	3 months post baseline
Secondary	Self-report change in physical fitness	Patient global change in self-perceived physical fitness measured on a 5-point Likert scale ranging from much better to much worse	6 months post baseline
Secondary	Self-report exercise habits	Questionnaire; self-report of exercise habits from baseline to 3 months post baseline: Participation in regular exercise (yes/no), if yes: frequency (1-2 times/week, 3-4 times/week, 5 times or more/week) and mode of exercise (endurance exercise, strength exercise, mobility exercise and/or other).; These questions are only forwarded to participants in the control group at this timepoint. Exercise habits form baseline to 3 months post baseline is recorded via the training diary for participants allocated to HIIT (experimental group): see outcome 153-157.	3 months post baseline
Secondary	Self-report exercise habits	Questionnaire; self-report of exercise habits from 3 months post baseline to 6 months post-baseline: Participation in regular exercise (yes/no), if yes: frequency (1-2 times/week, 3-4 times/week, 5 times or more/week) and mode of exercise (endurance exercise, strength exercise, mobility exercise and/or other).; These questions are forwarded to all study participants at this timepoint.	6 months post baseline
Secondary	Corona virus 19 infection	Questionnaire; self-report regarding corona virus 19 infection (yes/no, if yes: hospitalization/no hospitalization) from baseline to 3 months post baseline	3 months post baseline
Secondary	Corona virus 19 infection	Questionnaire; self-report regarding corona virus 19 infection (yes/no, if yes: hospitalization/no hospitalization) from 3 months post baseline to 6 montsh post baseline	6 months post baseline
Secondary	Corona virus 19 quarantine	Questionnaire; self-report regarding corona virus 19 quarantine (yes/no) from baseline to 3 months post baseline	3 months post baseline
Secondary	Corona virus 19 quarantine	Questionnaire; self-report regarding corona virus 19 quarantine (yes/no) from 3 months post baseline to 6 months post baseline	6 months post baseline
Secondary	Maximum minute ventilation at peak exercise (VEmax, L/min)	Maximum ventilation, recorded from CPET at peak exercise	Baseline
Secondary	Maximum minute ventilation at peak exercise (VEmax, L/min)	Maximum ventilation, recorded from CPET at peak exercise	3 months post baseline
Secondary	Maximum minute ventilation at peak exercise (VEmax, L/min)	Maximum ventilation, recorded from CPET at peak exercise	6 months post baseline

External Links

•   Effect of high-intensity exercise on cardiorespiratory fitness, cardiovascular disease risk and disease activity in patients with inflammatory joint disease: protocol for the ExeHeart randomised controlled trial